Skip to content

Study · Not a test of the peptide alone · 2025

2 results

Diverse Obesity Trajectories in a Family Including Identical Twins with a Pathogenic MC4R Variant.

Lim JJX, Hooper AJ, Khoo J, Loh WJ

Obesity facts25 Jun 2025

PMID40562024 (opens in a new tab)PMCIDPMC12270488 (opens in a new tab)DOI10.1159/000546795 (opens in a new tab)PepBankPUB-40562024
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In one man with obesity (BMI 35 kg/m2), severe insulin resistance and a pathogenic MC4R variant, a combination of semaglutide and naltrexone-bupropion reduced insulin requirements.

    In plain wordsIn one man with obesity and a gene variant, semaglutide taken together with naltrexone-bupropion was followed by lower insulin needs.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin requirements
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    In the proband with obesity (BMI 35 kg/m2) and severe insulin resistance, use of combination of semaglutide and naltrexone-bupropion was successful in reducing insulin requirements and weight.
    1 context sentence
    Summary · context
    Case Presentations: We report a pedigree with a pathogenic MC4R variant (c.380C>T, p.Ser127Leu).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In one man with obesity (BMI 35 kg/m2), severe insulin resistance and a pathogenic MC4R variant, a combination of semaglutide and naltrexone-bupropion reduced weight.

    In plain wordsIn one man with obesity and a gene variant, semaglutide taken together with naltrexone-bupropion was followed by weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    In the proband with obesity (BMI 35 kg/m2) and severe insulin resistance, use of combination of semaglutide and naltrexone-bupropion was successful in reducing insulin requirements and weight.
    1 context sentence
    Summary · context
    Case Presentations: We report a pedigree with a pathogenic MC4R variant (c.380C>T, p.Ser127Leu).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.